Ph.D. - Molecular Physiology/Toxicology at Kansas State University
D.V.M. - University of Khartoum, Sudan,
M.S. - Molecular Physiology/Toxicology at Kansas State University
Dr. Abdel-Mageed is a Professor of Urology at Tulane University School of Medicine, the Director of Molecular Oncology Research at Tulane University Health Sciences Center, the Zimmermann Endowed Professor of Cancer Research at the Tulane Cancer Center, and an adjunct professor in the Department of Pharmacology, the Center for Stem Cell Research and Regenerative Medicine, and the Graduate Program in Biomedical Sciences at Tulane. A former practicing veterinarian, he received his D.V.M. from the University of Khartoum in Sudan (1983), his M.S. (1989) and Ph.D. (1993) in Molecular Physiology and Toxicology from Kansas State University. Upon completing his postdoctoral fellowship in Tulane’s Department of Pharmacology (1994), he became a research instructor of pharmacology in 1996, subsequently joining the Department of Urology in 1997.
With a broad background in cancer research encompassing molecular and cellular biology and therapeutic approaches using in-vitro and in-vivo model systems, Dr. Abdel-Mageed and his research program have been continuously supported since 1997 by multiple grants from the National Cancer Institute (NCI), the National Center for Advancing Translational Sciences (NCATS), the National Institutes of Health (NIH), the US Department of Defense (DOD), and the American Cancer Society (ACS). Having received numerous awards during his academic career, including the American Association for Cancer Research Scholar Award, his research is marked by over 95 peer-reviewed publications and over 100 presentations at national and international meetings. While his long-standing translational research interests focus on molecular determinants of prostate cancer progression and prostate cancer health disparities, his current research also focuses on understanding the role of tumor-derived exosomes in mediating prostate cancer progression, with special emphasis on racial disparity of prostate cancer. Importantly, his research recently identified that lead compounds, via high-throughput strategies, can be repurposed to effectively target and inhibit exosome biogenesis/secretion and uptake by recipient cells.
Since his tenure at Tulane University School of Medicine, Dr. Abdel-Mageed has mentored over 50 graduate students, postdoctoral fellows, junior faculty members, and international scholars. In addition to his mentoring, researching, and teaching, he is a member of the NIH Steering Committee for the Extracellular RNA Communication Consortium (ERCC), the Vesicle Isolation and Function (VIF) subgroup of the ERCC, the NIH/TME Study Section, and the Internal Coordinating Committee for the NIH/NCI/Geographic Management of Cancer Health Disparities Programs (GMaP). Furthermore, he has served on numerous national and international study sections and review panels, including the ASC, DOD, NIH, Italian Academy of Sciences, Qatar National Foundation, and Singapore Medical Research Council.
Zakaria Y. Abd Elmageed, Yijun Yang, Raju Thomas, Manish Ranjan, Debasis Mondal, Krzysztof Moroz, Zhide Fang, Bashir M. Rezk, Krishnarao Moparty, Suresh C. Sikka, Oliver Sartor, and Asim B. Abdel-Mageed. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells (in press).
Zakaria Y. Abd Elmageed, Krzysztof Moroz, Sudesh K. Srivastav, Zhide Fang, Byron E. Crawford, Krishnarao Moparty, Raju Thomas, and Asim B. Abdel-Mageed. High circulating estrogens and selective expression of ERβ in prostate tumors of African Americans: Implications for racial disparity of prostate cancer. Carcinogenesis. 2013 May 8. [Epub ahead of print] 2013. PMID: 23658372
Hogyoung Kim, Zakaria Y. Abd Elmageed, Jihang Ju, Amarjit S. Naura, Asim B. Abdel-Mageed, Shibu Varughese, Dennis Paul, Suresh Alahari, Andrew Catling; Jong G. Kim; and A. Hamid Boulares. PDZK1 is a novel factor in breast cancer that is indirectly regulated by estrogen through IGF-1R and promotes estrogen-mediated growth. Mol. Med. 19(1):253-62, 2013. PMID: 23821363
Emad Kandi, Koji Tsumagari, Jingjing Ma, Zakaria Abd Elmageed, Xinying Li, Douglas Slakey, Debasis Mondal, Asim B Abdel-Mageed. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. J. Sur. Res., 2013 Apr 2. [Epub ahead of print], PMID: 23602735
Limin Ma, Yijun Yang, Suresh C. Sikka, Philip J. Kadowitz, Louis J. Ignarro, Asim B. Abdel-Mageed**, and Wayne J.G**. Hellstrom. Adipose tissue derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction. Proc. Natl. Acad. Sci., USA, 7;109(6):2090-5, 2012. PMID: 22308363 **joint senior author.
Qiuyang Zhang, Sen Liu, Dongxia Ge, Qingsong Zhang, Yun Xue, Zhenggang Xiong, Asim B. Abdel-Mageed, Leann Myers, Steven M. Hill, Brian G. Rowan, Oliver Sartor, Prescott L. Deininger, Jonathan Melamed, Zhenbang Chen, and Zongbing You. Interleulin-17 promotes formation and growth of prostate adenocarcinoma in mouse. Cancer Res., 2012, PMID: 22461511.
M. Mansour, D. Schwartz, Robert Judd, B. Akingbemi, T. Branden, J. Dennis, F. Bartoli, A. Hazi, I. Napier, and A. B. Abdel-Mageed. Thiazolidinediones/PPARÁ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int. J. Oncol., 2011 Feb;38(2):537-46. PMID: 21170507
J. Ju, A.S. Naura, .Y Errami; M. Zerfaoui, H. Kim, J.G. Kim, Z.Y. Abd Elmageed, A.B. Abdel-Mageed, C. Giardina, A. A. Beg, M. E. Smulson, and A. H. Boulares. Phosphorylation of p50 NF-κB at a single serine residue by DNA-dependent protein kinase is critical for VCAM-1 expression upon TNF Treatment. J. Biol. Chem., 2010 Dec 24;285(52):41152-60. [Epub ahead of print] PMID: 20966071.
Tisheeka R. Graham, Krishna C. Agrawal, A. B. Abdel-Mageed. Independent and cooperative roles of TNF-α, NF-κB, and BMP-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells. Cancer Science, 101(1):103-11, 2009. PMID: 19811499.
Tisheeka Graham, Valerie Odero-Marah, Leland WK Chung, Krishna C. Agrawal, and Asim B. Abdel-Mageed. PI3K/Akt-Dependent Transcriptional Regulation and Activation of BMP-2-Smad Signaling by NF-κB in Metastatic Prostate Cancer Cells. Prostate, 69:168-80, 2008. PMID: 18942118
Promil Kukreja, Asim B. Abdel-Mageed, Debasis Mondal, Krishna C. Agrawal. SDF-1α up-regulates expression of the chemokine receptor CXCR4 in PC3 cells via a MEK-ERK dependent NF-κB activation. Cancer Res. 1;65(21):9891-8, 2006.
Rodney Davis, Dingwu Jia, Bekir Cinar, Suresh. C. Sikka, Krishnarao Moparty, Haiyen E. Zhau, Leland W. Chung, Krishna.C. Agrawal and A. B. Abdel-Mageed. Functional androgen receptor confers sensitization of androgen independent prostate cancer cells to anticancer therapy via caspase activation. Biochem. Biophy. Res. Commun., 309:937-45, 2003.
Vincent Flynn, Jr., Anshiya Ramanitharan, Krishnaro Moparty, Rodney Davis, Suresh Sikka, Krishna C. Agrawal, A. B. Abdel-Mageed. Adenovirus-mediated inhibition of NF-κB conferschemosensitization and apoptosis in prostate cancer cells. Int. J. Oncol., 23: 317-323, 2003.
Andrew Nguyen, Z. Jing, S. Mahoney, Rodeny Davis, Suresh C. Sikka, Krishna C. Agrawal and Asim B. Abdel-Mageed:. In vivo gene expression profile analysis of metallothionein in renal cell carcinoma. Cancer Lett, 160:133-140, 2000.
A. B. Abdel-Mageed and Krishna C. Agrawal: Activation of NF-kappa B: potential role in metallothionein-mediated mitogenic response. Cancer Res., 58:2335-2338, 1998.
A. B. Abdel-Mageed and Krishna C. Agrawal. Antisense down-regulation of metallothionein induces growth inhibition and apoptosis in human breast carcinoma MCF7 cells. Cancer Gene Therapy. 4:199-207, 1997.
For more information about Dr. Asim Abdel-Mageed's publications, visit PubMed.